Accustem Sciences (QB)【ACUT】銘柄情報

Accustem Sciences Inc (QB) (ACUT) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.256

( - )

買値

0.23

売値

0.4621

出来高

0.00 日の範囲 0.00

0.256 52 週間の範囲 2.33

時価総額

4.115M

前日終値

0.256

始値

時刻

0.2316

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 3,305

発行済株式数

16,072,267

配当利回り

PER

-2.26

1 株当たり利益 (EPS)

-0.12

歳入

純利益

-1.8M

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomogra... AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

accustem.com

本社

New York, United States

設立

2026

Accustem Sciences Inc (QB) is listed in the Healthcare sector of the その他OTC with ticker ACUT. The last closing price for Accustem Sciences (QB) was US$0.26. Over the last year, Accustem Sciences (QB) shares have traded in a share price range of US$ 0.256 to US$ 2.33.

Accustem Sciences (QB) currently has 16,072,267 shares in issue. The market capitalisation of Accustem Sciences (QB) is US$4.11 million. Accustem Sciences (QB) has a price to earnings ratio (PE ratio) of -2.26.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)

PHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning

PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a...

AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th

PHOENIX and LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.10005	-28.099985957	0.35605	0.35605	0.256	132	0.31610608	CS
4	-0.034	-11.724137931	0.29	0.35605	0.256	3951	0.26867334	CS
12	-0.1197	-31.8605270162	0.3757	0.4799	0.256	3381	0.31966607	CS
26	-0.53665	-67.7032738283	0.79265	0.846	0.256	2429	0.42661142	CS
52	-0.394	-60.6153846154	0.65	2.33	0.256	3545	1.09410107	CS
156	-0.724	-73.8775510204	0.98	2.33	0.2159	4917	0.70028566	CS
260	-1.394	-84.4848484848	1.65	3	0.2159	4899	0.81527938	CS